Factors | Univariate | Multivariate | |||
---|---|---|---|---|---|
P value | HR | 95%CI | P value | ||
Gender(M/F) | 0.880 | Â | Â | Â | |
Age(≤60/>60y) | 0.917 |  |  |  | |
Tumor type (naïve/recurrent) | 0.137 |  |  |  | |
Surgery history of liver (Y/N) | 0.564 | Â | Â | Â | |
Etiology (Hepatitis/others) | 0.315 | Â | Â | Â | |
Liver cirrhosis (Y/N) | 0.229 | Â | Â | Â | |
Antiviral treatment (Y/N) | 0.122 | Â | Â | Â | |
ECOG performance status (0/1) | 0.877 | Â | Â | Â | |
Child-Pugh (A/B) | 0.292 | Â | Â | Â | |
BCLC stage of primary HCC (A/B) | 0.873 | Â | Â | Â | |
AFP (≥400/< 400 μg/L) | 0.283 |  |  |  | |
PLT (≥100/< 100 × 109/L) | 0.529 |  |  |  | |
PT (≤14/> 14 s) | 0.901 |  |  |  | |
ALB (≤35/> 35 g/L) | 0.254 |  |  |  | |
ALT (≤40/> 40 IU/L) | 0.518 |  |  |  | |
TB (≤17.1/> 17.1 mol/L) | 0.886 |  |  |  | |
Tumor number (single /multiple) | 0.101 | Â | Â | Â | |
Location (Paracaval portion/ Caudate process/ Spiegel’s lobe) | 0.069 |  |  |  | |
Tumor size (≤2 cm /> 2 cm) | 0.720 |  |  |  | |
Puncture approach (LA/ RA/ combination approach) | 0.809 | Â | Â | Â | |
Treatment strategy | RFA/ EA/ RFA-EA | 0.960 | Â | Â | Â |
EA/RFA or RFA-EA | 0.807 | Â | Â | Â | |
RFA or EA/RFA-EA | 0.529 | Â | Â | Â | |
AM (≥ 5 mm / < 5 mm) | 0.189 |  |  |  | |
LTP (Y/N) | 0.890 | Â | Â | Â | |
Major complication (Y/N) | 0.172 | Â | Â | Â |